Effects of aglepristone, a progesterone receptor antagonist, in a dog with a vaginal fibroma

• Published in: Journal of small animal practice 2008, Vol.49 (1), p.41-43
• Main Authors: Rollón, E., Millán, Y., De Las Mulas, J. Martín
• Format: Article
• Language: English
• Subjects: aglepristone; agonists; Animals; case studies; dog diseases; Dog Diseases - drug therapy; Dog Diseases - surgery; Dogs; drug therapy; Estrenes - therapeutic use; Female; females; fibroma; Fibroma - drug therapy; Fibroma - surgery; Fibroma - veterinary; hormone receptors; immunohistochemistry; progesterone; Receptors, Progesterone - antagonists & inhibitors; signs and symptoms (animals and humans); subcutaneous injection; Treatment Outcome; vagina; vaginal diseases; Vaginal Neoplasms - drug therapy; Vaginal Neoplasms - surgery; Vaginal Neoplasms - veterinary
• ISSN: 0022-4510; 1748-5827
• DOI: 10.1111/j.1748-5827.2007.00424.x

A 12-year-old, entire, nulliparous crossbreed female dog was presented with a history of vulval bleeding, bulging of the perineum and faecal tenesmus. A firm, non-painful perineal mass, measuring 9·11x5·4 cm, with erythema was detected. Abdominal radiography showed compression and elevation of the rectal ampulla. A dose of 10 mg/kg aglepristone was administered subcutaneously on days 1, 2, 8, 15, 28 and 35. An incision biopsy was taken on day 15 and immunohistochemical analysis showed that the majority of neoplastic cells expressed progesterone receptors. Both the cutaneous erythema and the faecal tenesmus had resolved by day 28. A 50 per cent reduction in size was observed by day 60 (surgical excision). This study shows that benign tumours of the vagina of the dog that contain progesterone receptors can be reduced in size in a palliative or neoadjuvant setting using the progesterone receptor antagonist aglepristone.